No firmer information has yet been released on the nature of the reaction, or when it happened, although a source reportedly claimed the participant in question is expected to make a full recovery.
A spokesperson for AstraZeneca, a company working with Oxford University to create a potential vaccine, said the company’s “standard review process triggered a pause to vaccination to allow review of safety data.”
A large Phase 3 study on the effects of the AstraZeneca and Oxford University Covid-19 vaccine on humans has been put on hold after a participant in a UK study reportedly suffered “a serious adverse reaction”
The company helping Oxford University to produce its promising Coronavirus vaccine has announced it has suspended testing of the potential medicine to conduct a “review of safety data” after a volunteer suffered a negative reaction to the drug.
This comes as last month it was reported the government has insisted the UK will be the first in line for a coronavirus vaccine created by Oxford University.
The spokesperson explained the pause is “a routine action which has to happen whenever there is a potentially unexplained illness in one of the trials, while it is investigated, ensuring we maintain the integrity of the trials.”
Initial human trials suggest it is safe and creates an immune response to Covid-19.
A Number 10 spokesman today said: “We have been clear that we will only roll out a vaccine once it is deemed safe and effective by our regulators.”
Its scientific agencies reportedly said a vaccine would need to be studied in 30,000 people before it could be authorised.
However, it is not likely to be ready until next year.
Boris Johnson’s government has struck a deal with AstraZeneca to get “first access” to it once approved, the spokesman added.
“AstraZeneca have entered into a number of agreements with other countries, they have the global licensing agreement with Oxford, but we have been clear: once it has been found to be effective, we have signed a deal for 100 million doses which means that once it is effective the UK will get first access.”